Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Endometrial Neoplasms 19Ovarian Neoplasms 8Uterine Cervical Neoplasms 7Triple Negative Breast Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4Neoplasms 4Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Colorectal Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma, Renal Cell 3Carcinoma, Ovarian Epithelial 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Vulvar Neoplasms 2Thyroid Neoplasms 2Neoplasm Metastasis 2Fallopian Tube Neoplasms 2Advanced Endometrial Cancer 2Adenocarcinoma 2Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Pancreatic Neoplasms 1Ovarian Diseases 1Ovarian Clear Cell Carcinoma 1Neoplasms, Glandular and Epithelial 1Melanoma 1Liver Neoplasms 1

Interventions

pembrolizumab 3Paclitaxel 3Carboplatin 3niraparib 2anlotinib 2Pemetrexed 2Palliative Care 2Interviews as Topic 2Gemcitabine 2Educational Status 2Bevacizumab 2temsirolimus 1relacorilant 1olaparib 1nilotinib 1liposomal doxorubicin 1lenvatinib 1Watchful Waiting 1Transurethral Resection of Prostate 1Topotecan 1Therapeutic Touch 1Radiotherapy 1Pregnancy Tests 1Ocoxin 1Nivolumab 1Methods 1Laparoscopy 1Human Papillomavirus DNA Tests 1Fulvestrant 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Genital Neoplasms, Female × lenvatinib × Gynecologic × Clear all
NCT04519151 2023-06-08

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Sheba Medical Center

Phase 2 Recruiting
24 enrolled
GastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Genital Neoplasms, Female, Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Stomach Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡